Finance

Lists
TYRA:NASDAQ
Tyra Biosciences Inc
$23.54
0.00%
(0.00) 1D
Sep 10, 4:00:01 PM GMT-4  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for TYRA...
Mkt. cap
1.40B
Avg. vol.
881.73K
Volume
943.00
52-wk high
$40.65
52-wk low
$11.82
EPS
-$2.39
Beta
0.73
Shares outstanding
59.68M
No. of employees
87
Mkt. cap
1.40B
Avg. vol.
881.73K
Volume
943.00
52-wk high
$40.65
52-wk low
$11.82
EPS
-$2.39
Beta
0.73
Shares outstanding
59.68M
No. of employees
87
News stories
From web sources and news partners
About Tyra Biosciences Inc
CEO-
Employees87
Founded2018
HeadquartersCarlsbad, California, United States
SectorBiotechnology
Websitetyra.bio
Analyst ratings
Based on 11 analysts giving stock ratings to TYRA in the past 3 months
Strong buy
Buy
11
Hold
0
Sell
0
12-month forecast
Based on 11 Wall Street analysts offering 12 month price targets for TYRA in the last 3 months.
Highest
Current $23.54
$59.00 (+150.64%)
Average
$48.33 (+105.31%)
Lowest
$30.00 (+27.44%)
Analyst
Recommendation
Action
Price target
Projected
Date
Boris Peaker
JonesTrading
Buy
Reiterated
$56.00
+137.9%
09/10/2026
Eliana Merle
Barclays
Buy
Maintained
$59.00
+150.6%
09/10/2026
Sami Corwin
William Blair
Buy
Maintained
-
-
09/09/2026
John Newman
Canaccord Genuity
Buy
Maintained
$50.00
+112.4%
09/10/2026
Mitchell Kapoor
H.C. Wainwright
Buy
Reiterated
$30.00
+27.4%
09/10/2026
Allison Bratzel
Piper Sandler
Buy
Maintained
$56.00
+137.9%
09/08/2026
Jason Zemansky
Bank of America Securities
Buy
Maintained
$39.00
+65.7%
09/08/2026
Maury Raycroft
Jefferies
Buy
Maintained
$42.00
+78.4%
08/05/2026
Robert Driscoll
Wedbush
Buy
Maintained
$53.00
+125.1%
08/05/2026
Matthew Biegler
Oppenheimer
Buy
Reiterated
$50.00
+112.4%
07/31/2026
Mazahir Alimohamed
Oppenheimer
Buy
Reiterated
$50.00
+112.4%
07/31/2026
Christopher Raymond
Raymond James
Buy
Maintained
-
-
07/17/2026
Kalpit Patel
Wolfe Research
Hold
Initiated
-
-
05/19/2026
Unknown Analyst
Jefferies
Buy
Maintained
$44.00
+86.9%
05/14/2026
Tyler Van Buren
TD Cowen
Buy
Maintained
-
-
05/13/2026
Bradley Canino
Guggenheim
Buy
Initiated
$54.00
+129.4%
04/15/2026
Li Watsek
Cantor Fitzgerald
Buy
Maintained
-
-
03/04/2026
Last report
Aug 4, 2026
Fiscal period
Q2 2026
EPS / Est. (USD)
-$0.69 / -$0.64
-7.02%miss
Revenue / Est. (USD)
- / 0.00
Fiscal Q2 2026 earnings call
Waiting for the earnings call
At a glance
Insights from the latest news and reports
Previous reportsAll values in USD
Loading Previous Earnings...
Income statement
Revenue
Net income
All values in USD
Sep 2025
Dec 2025
Mar 2026
Jun 2026
Revenue
-
-
-
-
Cost of goods sold
-
-
-
-
Cost of revenue
-
-
-
-
Research and development expenses
25.47M
28.19M
33.47M
39.20M
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
7.48M
8.33M
8.53M
9.81M
Operating expense
32.94M
36.52M
42.00M
49.00M
Total operating expenses
32.94M
36.52M
42.00M
49.00M
Operating income
-32.94M
-36.52M
-42.00M
-49.00M
Other non operating income
-
-
-
-
EBT including unusual items
-29.87M
-33.83M
-39.30M
-45.56M
EBT excluding unusual items
-29.87M
-33.83M
-39.30M
-45.56M
Income tax expense
-
-
-
-
Effective tax rate
-
-
-
-
Other operating expenses
-
-
-
-
Net income
-29.87M
-33.83M
-39.30M
-45.56M
Net profit margin
-
-
-
-
Earnings per share
-0.50
-0.57
-0.64
-0.69
Interest and investment income
3.08M
2.68M
2.69M
3.44M
Interest expense
-
-
-
-
Net interest expenses
3.08M
2.68M
2.69M
3.44M
Depreciation and amortization charges
-
-
-
-
EBITDA
-32.81M
-36.38M
-41.86M
-48.86M
Gain or loss from assets sale
-
-
-
-
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer
Google apps